Halting progression of renal failure: Consideration beyond angiotensin II inhibition

Nephrology Dialysis Transplantation

Volumn 17, Issue 11, 2002, Pages 1871-1075

  Salahudeen, Abdulla K ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

ACEI; ARB; Chronic kidney disease; ESRD; Non renal factors; Renal failure progression

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; ANGIOTENSIN II;

CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFICACY; EDITORIAL; EDUCATION; ENZYME INHIBITION; GENETIC RISK; HEALTH CARE ACCESS; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; LOW BIRTH WEIGHT; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN INTAKE; RACE DIFFERENCE; RISK FACTOR; SMOKING HABIT; SOCIAL STATUS; SOCIOECONOMICS; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; PATHOPHYSIOLOGY;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 0036842155     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.11.1871     Document Type: Editorial

References (27)

1. Incidence and prevalence of ESRD. USRDS. United States Renal Data System. Am J Kidney Dis 1997; 30: S40-S53
2. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-2758
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
4. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863
5. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364
6. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
8. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J Am Med Assoc 2001; 285: 2719-2728
9. Locatelli F, Del Vecchio L, Andrulli S. REIN follow-up trial. Ramipril efficacy in nephropathy. Lancet 1998; 352: 2020-2022
10. Parfrey PS. Hereditary renal diseases. Curr Opin Nephrol Hypertens 1993; 2: 192-200
11. Jacobsen P, Rossing K, Rossing P et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998; 53: 1002-1006
12. Pfohl M, Frost D, Koch M et al. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting-enzyme gene and diabetic nephropathy in IDDM patients. Horm Metab Res 1998; 30: 276-280
13. Perna A, Ruggenenti P, Testa A et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney Int 2000; 57: 274-281
14. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int Sappl 1997; 63: S124-S127
15. Lackland DT, Bendall HE, Osmond C, Egan BM, Barker DJ. Low birth weights contribute to high rates of early-onset chronic renal failure in the southeastern United States. Arch Intern Med 2000; 160: 1472-1476
16. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389
17. Salahudeen AK, Kanji V, Reckelhoff JF, Schmidt AM. Pathogenesis of diabetic nephropathy: a radical approach. Nephrol Dial Transplant 1997; 12: 664-668
18. Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000; 58: S120-S125
19. Keane WE. Lipids and the kidney. Kidney Int 1994; 46: 910-920
20. Massy ZA, Khoa TN, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999; 14: 2392-2397
21. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509
22. Salahudeen AK, Hostetter TH, Raatz SK, Rosenberg ME. Effects of dietary protein in patients with chronic renal transplant rejection. Kidney Int 1992; 41: 183-190
23. Orth SR. Smoking - a risk factor for progression of renal disease. Kidney Blood Press Res 2000; 23: 202-204
24. Remuzzi G. Cigarette smoking and renal function impairment. Am J Kidney Dis 1999; 33: 807-813
25. Mayberry RM, Mili F, Ofili E. Racial and ethnic differences in access to medical care. Med Care Res Rev 2000; 57: 108-145
26. Hoeldtke NJ, Hoeldtke KC. Inequalities in racial access to health care. J Am Med Assoc 2000; 284: 2053
27. Krop JS, Coresh J, Chambless LE et al. A community-based study of explanatory factors for the excess risk for early renal function, decline in blacks vs whites with diabetes: the Atherosclerosis Risk in Communities study. Arch Intern Med 1999; 159: 1777-1783